Koroner bypass, Everolimus, Perkütan koroner müdahale, Syntax skoru, çok damar hastalığı.
Generally, surgical revascularization recommended for patients who have high SYNTAX scores, but it is the greatest desire of invasive cardiologists to have a reliable “Plan B” in cases with high surgery risk. For this reason, the purpose of the present study was to compare medical treatment alone, surgical-medical treatment, and percutaneous-medical treatment options in CCS cases with a SYNTAX score of ≥33. In an observational registry study, we included patients with multivessel disease and SYNTAX score of ≥33. Both short (30-day) and long-term outcomes of subjects in all three treatment arms were evaluated. The primary outcome was allcause and cardiac mortality. Myocardial infarction, revascularization, and stroke constituted our secondary outcomes. 33 patients in the MT arm, 24 in the PCI arm, and 79 in the CABG arm were included in the analyses. Mean follow-up was 48.25±26.37 months. CABG arm was superior to both arms in terms of cardiac death (CABG vs MT p=0.001, CABG vs PCI p=0.001) and PCI and MT did were similar (p=0.085), CABG was superior in allcause detah (CABG vs MT p=0.002, CABG vs PCI p=0.002) again no statistical differences were detected between MT and PCI arms (p=0.065) in long term follow-up. In terms of acute myocardial infarction(AMI) (CABG vs MT p=<0.001, CABG vs PCI p=<0.001), cerebrovascular event(CVE) (CABG vs MT p=0.04, CABG vs PCI p=0.015) , additional revascularization CABG was superior side again (CABG vs PCI p=<0.001). AMI was higher in MT group compare to PCI (p=0.025). CVE were similar in MT and PCI groups (p=0.65). İn cases with CCS and ≥33 SYNTAX score, CABG is superior to MT alone and PCI which is performed with everolimus-eluting stents in terms of cardiac death, allcause mortality, AMI and CVE in long term follow-up.
Coronary artery bypass, Everolimus, Percutaneous coronary intervention, SYNTAX score, Multivessel disease
|Konular||Sağlık Bilimleri ve Hizmetleri|
|Bölüm||ORİJİNAL MAKALELER / ORIGINAL ARTICLES|
|Yayımlanma Tarihi||14 Mart 2022|
|Yayınlandığı Sayı||Yıl 2022, Cilt 44, Sayı 3|